Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4385360 | 0.99 | MAPK14 (0.57) | MAPK14SLC6A4GRM2HTR2AHTR2C | |
| SCHEMBL6109063 | 0.87 | MAPK14 (0.62) | MAPK14SLC6A4GRM2HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4385176 | 0.86 | MAPK14 (0.61) | MAPK14SLC6A4GRM2HTR1ASLC6A2 | |
| SCHEMBL1037340 | 0.85 | MAPK14 (0.70) | MAPK14GRM2 | |
| SCHEMBL3518367 | 0.82 | MAPK14 (0.38) | MAPK14SLC6A4HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL3525831 | 0.82 | MAPK14 (0.38) | MAPK14SLC6A4HTR2AHTR2C | |
| SCHEMBL27602597 | 0.77 | MAPK14 (0.52) | MAPK14GRM2 | |
| SCHEMBL4469661 | 0.76 | MAPK14 (0.61) | MAPK14SLC6A4GRM2HTR2AHTR2C | |
| SCHEMBL27602666 | 0.76 | MAPK14 (0.56) | MAPK14GRM2 | |
| SCHEMBL4376318 | 0.74 | MAPK14 (0.65) | MAPK14SLC6A4GRM2HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885SLC6A4 2952/4885GRM2 1349/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885SLC6A4 2452/4885GRM2 1436/4885 |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 46/4885SLC6A4 3383/4885GRM2 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.